Browse by Audience
There is renewed emphasis on including patients in determining, defining, and prioritizing outcomes for migraine treatment.
Learn More >Over the past decade, psychedelic compounds have emerged as potentially transformative therapeutics for a variety of intractable neuropsychiatric conditions. However, historically most of the basic science has utilized these compounds […]
Learn More >The nucleus accumbens (NAc) is a key brain region involved in reward processing and is linked to multiple neuropsychiatric conditions such as substance use disorder, depression, and chronic pain. Recent […]
Learn More >This study aims to profile migraine patients according clinical and psychophysical characteristics.
Learn More >Cannabidiol (CBD) is the main pharmacologically active phytocannabinoid. CBD exerts an analgesic effect in several pain models, does not have side effects and has low toxicity. The data about CBD […]
Learn More >Itch is an annoying sensation consisting of both sensory and emotional components. It is known to involve the parabrachial nucleus (PBN), but the following transmission nodes remain elusive. The present […]
Learn More >Current topical treatment options for seborrheic dermatitis are limited by efficacy and/or safety.
Learn More >Depression is associated with an increased risk of physical illness, but the most common causes of hospitalization among people with depression are unclear.
Learn More >Chronic pain and mental disorders are leading causes of disability worldwide. Individuals with chronic pain are more likely to experience mental disorders compared to individuals without chronic pain, but large-scale […]
Learn More >